高剂量率近距离放射治疗原发性非小细胞肺癌的研究进展

Research progress of high-dose-rate brachytherapy for primary non-small cell lung cancer

非小细胞肺癌(NSCLC)是肺癌最常见的组织病理学类型之一,约占肺癌的85%~90%。目前,手术切除是NSCLC的首选治疗方法,但仍有部分NSCLC患者因各种原因不适宜手术或者拒绝手术,因此,针对该类NSCLC患者的局部治疗成为研究热点。高剂量率近距离放射治疗(HDR-BT)是一种较新的治疗方式,且在治疗NSCLC方面具有较好的疗效。笔者通过分析国内外现有的相关HDR-BT文献,对其治疗NSCLC的安全性和疗效以及与立体定向放射治疗、射频消融和125I粒子植入术等其他局部治疗方式的异同进行综述。

Non-small-cell lung cancer(NSCLC)is the most common histopathological type of lung cancer,accounting for about 85%−90%of lung cancer.At present,surgical resection is the first choice for NSCLC,but there are still some patients who are not suitable for surgery or refuse surgery because of various reasons.Therefore,the local treatment for this kind of NSCLC patients has become the research hotspot.High-dose-rate brachytherapy(HDR-BT)is a new modality for the treatment of NSCLC,has good efficacy in the treatment of NSCLC.By analyzing the existing HDR-BT literature at home and abroad,the authors review the safety and efficacy of HDR-BT in the treatment of NSCLC as well as its similarities and differences with other local therapeutic modalities such as stereotactic body radiation therapy,radio frequency ablation and 125I seed implantation by analyzing the existing relevant literature on HDR-BT at home and abroad.